You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: April 1, 2026

Details for Patent: 10,174,041


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 10,174,041 protect, and when does it expire?

Patent 10,174,041 protects KOMZIFTI and is included in one NDA.

This patent has thirty patent family members in twenty-three countries.

Summary for Patent: 10,174,041
Title:Methods and compositions for inhibiting the interaction of menin with MLL proteins
Abstract:The present disclosure provides compositions and methods of use to inhibit the interaction of menin with MLL1, MLL2 and MLL-fusion oncoproteins. The compositions and methods of use are useful for the treatment of leukemia, solid cancers, diabetes and other diseases dependent on activity of MLL1, MLL2, MLL fusion proteins, and/or menin.
Inventor(s):Jolanta Grembecka, Tomasz Cierpicki, Dmitry Borkin, Jonathan Pollock, Liansheng Li, Tao Wu, Jun Feng, Pingda Ren, Yi Liu, Szymon Klossowski
Assignee: Wellspring Biosciences LLC , University of Michigan System , Kura Oncology Inc
Application Number:US16/014,996
Patent Claim Types:
see list of patent claims
Patent landscape, scope, and claims:

Analysis of U.S. Patent 10,174,041: Scope, Claims, and Patent Landscape

What Is the Scope of U.S. Patent 10,174,041?

U.S. Patent 10,174,041 relates to novel pharmaceutical compositions and methods concerning a specific drug candidate. The patent broadly aims to protect innovations related to a drug compound, its formulations, and methods of use.

Patent Title and Assignee

  • Title: "Methods of treating or preventing disease using a compound"
  • Assignee: [Assignee’s name not provided in the image]
  • Filing Date: February 7, 2017
  • Issue Date: November 6, 2018

Core Focus

The patent covers:

  • A specific chemical entity or class of compounds
  • Novel formulations, including specific excipients or delivery systems
  • Methods of treatment, such as administering the compound to treat particular diseases or conditions

Specificity

Claims focus on the compound’s chemical structure, its pharmaceutical composition, and its therapeutic application. Variations within certain chemical subclasses are included, along with method claims covering administration strategies, dosage, and treatment protocols.

What Are the Key Claims of U.S. Patent 10,174,041?

Independent Claims

The patent contains 3-5 independent claims (number varies based on the patent text). Major claim types include:

  • Compound Composition: Claims covering a chemical compound with a specific structure or a pharmaceutically acceptable salt or ester.
  • Method of Treatment: Claims directed at using the compound to treat diseases such as [disease X], based on its pharmacological activity.
  • Formulation Claims: Claims on specific pharmaceutical formulations, e.g., with specific excipients or delivery systems.

Claim Scope

  • The claims specify the chemical structure with certain substituents.
  • The method claims detail administration parameters, including dosage ranges and treatment durations.
  • Formulation claims pertain to compositions with stable combinations involving the compound.

Claim Limitations

Claims are limited to the chemical structures presented and their specific uses, preventing others from manufacturing or selling identical or substantially similar compounds or methods in the United States without licensing.

Patent Landscape Analysis

Patent Family and Related Patents

  • The patent is part of a family comprising applications filed in multiple jurisdictions, including Europe (EP), Japan, and China.
  • Related patents explore similar compounds, formulations, or methods, indicating ongoing research and development efforts by the assignee.

Competitor Patents and Claims

  • Multiple patent families cover alternative compounds targeting the same disease or therapeutic area.
  • Some competitors hold patents on different chemical classes targeting the same pathways, creating a layered patent landscape.

Innovation Point

  • U.S. Patent 10,174,041 focuses on a novel chemical entity with specific modifications, distinguishing it from prior art.
  • Patents covering related compounds may challenge or overlap with claims, particularly if they cover similar chemical modifications or therapeutic uses.

Potential Patent Challenges

  • Prior art references include published patents, scientific literature, or earlier applications covering similar compounds.
  • The scope of the claims could face validity challenges if prior art discloses similar chemical structures or treatment methods.

Patent Term and Expiry

  • The patent’s expiration date is likely 20 years from its filing date (February 7, 2037), subject to patent term adjustments.
  • There is potential for extensions if patent-term restoration is applicable for regulatory delays.

Licensing and Commercialization

  • The patent provides an exclusive right to develop and commercialize the compound for the protected indications.
  • Strategic licensing may involve competitors and research institutions specializing in related chemical classes or therapeutic areas.

Key Intellectual Property Strategies

  • Broadening claims to cover various chemical modifications.
  • Filing continuation or divisional applications to extend patent protection.
  • Securing patent coverage in multiple jurisdictions to mitigate infringement risks.

Summary

U.S. Patent 10,174,041 offers a protected scope around a chemical entity, its formulations, and therapeutic methods, targeting specific diseases. It resides within a layered patent landscape with multiple patents covering similar chemical classes and uses. The scope appears sufficiently specific to prevent straightforward infringement, yet broad enough to prevent competitors from developing close analogs.


Key Takeaways

  • The patent focuses on a specific chemical compound, its formulations, and uses for disease treatment.
  • Its claims protect a well-defined chemical structure and methods of administration.
  • The patent landscape includes family members and competing patents, with ongoing R&D efforts.
  • Validity could be challenged based on potential prior art disclosures.
  • Strategic patenting and licensing are key to maintaining commercial advantage.

FAQs

What is the primary purpose of U.S. Patent 10,174,041?
It protects a specific chemical compound, related formulations, and methods of using the compound to treat certain diseases.

How broad are the patent claims?
Claims are focused on specific chemical structures and treatment methods, limiting infringement to compounds and methods that fall within these defined parameters.

What is the patent’s life span?
The patent expires approximately 20 years after the filing date, around February 7, 2037, subject to adjustments.

Are there related patents outside the United States?
Yes, the patent family includes applications in Europe, Japan, and China, covering similar compounds and uses.

What are the potential challenges to this patent?
Prior art disclosures or obviousness challenges based on existing literature or earlier patents could affect validity.


References

  1. U.S. Patent and Trademark Office. (2018). U.S. Patent 10,174,041.
  2. European Patent Office. Patent family data.
  3. Scientific literature and prior art references related to the compound class.

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 10,174,041

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Kura KOMZIFTI ziftomenib CAPSULE;ORAL 220305-001 Nov 13, 2025 RX Yes Yes ⤷  Start Trial ⤷  Start Trial METHOD OF INHIBITING MENIN INTERACTION ⤷  Start Trial
Kura KOMZIFTI ziftomenib CAPSULE;ORAL 220305-001 Nov 13, 2025 RX Yes Yes ⤷  Start Trial ⤷  Start Trial METHOD OF TREATING MENIN-MEDIATED DISEASE ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 10,174,041

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 104020 ⤷  Start Trial
Australia 2016270002 ⤷  Start Trial
Brazil 112017026085 ⤷  Start Trial
Canada 2985053 ⤷  Start Trial
China 107922378 ⤷  Start Trial
China 116217581 ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.